Dr Hendriks is a pulmonologist specialising in thoracic oncology at the Maastricht University Medical Center, the Netherlands, where she leads the clinical lung cancer research department. Her research line is focussing on brain metastases in patients with lung cancer (obtaining a PhD on this topic in 2016), neurocognition, oligometastases and locally advanced disease. In 2017-2018, she carried out postdoctoral research on brain metastases and immunotherapy in Gustave Roussy, France under the mentorship of prof. Besse.

Dr Hendriks is the representative for thoracic oncology in the Maastricht UMC Comprehensive Cancer Cancer, and chairs the Innovative Cancer Diagnostics Therapy group at the School for Oncology and Developmental Biology (GROW) at Maastricht University, where she is also appointed as assistant professor. She is heavily involved in clinical and translational research, and is (local) principal investigator in several phase II and III clinical trials, focusing on (locally) advanced NSCLC and SCLC, targeted treatments and immunotherapies.

She is an active member of Dutch (NVALT, NRS), European (ESMO, EORTC, ETOP, ERS) and global societies (IASLC, ASCO), is secretary of the NVALT studies foundation, vice-chair of the scientific committee of the Dutch Thoracic Group and chairs the EORTC sub-committee on Systemic Treatment for metastatic NSCLC.

Dr Hendriks was the lead author of the revised ESMO Clinical Practice Guidelines on metastatic NSCLC and author of the ESMO Clinical Practice Guideline on SCLC. She is member of the Dutch guideline committees on NSCLC, brain metastases and leptomeningeal metastases. Dr Hendriks is an active program committee member or chair of several national and international conferences and masterclasses. In 2021, she was elected as member of the Young Academy of the Royal Netherlands Academy of Arts and Sciences.